BiotechTube
Delpharm

Delpharm

Paris, France· Est.
delpharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Delpharm is a major international player in the pharmaceutical CDMO sector, ranking among the world's top five. With 18 manufacturing sites and 3 development centers across Europe and North America, it generates over €1.1 billion in revenue and employs approximately 6,500 people. The company offers end-to-end services from development to commercial manufacturing, with noted expertise in complex dosage forms like nasal sprays, serving a broad client base of pharmaceutical companies.

Drug Delivery

Technology Platform

Integrated network of GMP facilities for development and manufacturing of solid, sterile, semi-solid, and liquid dosage forms, with specialized expertise in nasal spray production.

Opportunities

The growing trend of pharmaceutical outsourcing, especially for complex dosage forms and by virtual biotechs, presents a significant expansion opportunity.
Specialization in high-value areas like nasal sprays and sterile injectables allows Delpharm to capture higher-margin work within the broader CDMO market.

Risk Factors

Key risks include client concentration, operational execution risk (quality failures, supply disruptions), intense price competition in the CDMO sector, and dependency on the success and outsourcing decisions of its pharmaceutical clients.

Competitive Landscape

Delpharm competes in a fragmented but consolidating global CDMO market against other large players like Lonza, Catalent, Recipharm, and Siegfried. Its competitive advantage lies in its scale (top 5 global), broad dosage form expertise, and strategic geographic network of facilities in Europe and North America.

More companies in Small Molecule Drugs →More companies in France →